Current approaches with the glutamatergic system as targets in the treatment of neuropathic pain

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 8, 2009, Pages 925-943

  Yogeeswari, Perumal ^a   Semwal, Arvind ^a   Mishra, Ramkumar ^a   Sriram, Dharmarajan ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

AMPA antagonist; Glutamate; Glutamate transporters; Kainate antagonist; mGluR antagonist; NAALADase; Neuropathic pain; NMDA antagonist; Pain

Indexed keywords

2 [5 (4 DIMETHYLSULFAMOYLPHENYL) 6,7,8,9 TETRAHYDRO 8 METHYL 2 OXO 1H PYRROLO[3,2 H]ISOQUINOLIN 3 YLIMINOXY] 4 HYDROXYBUTYRIC ACID; 4,6 DICHLORO 3 (2 OXO 1 PHENYL 3 PYRROLIDINYLIDENEMETHYL) 1H INDOLE 2 CARBOXYLIC ACID; 5 CHLORO 7 TRIFLUOROMETHYL 2,3 QUINOXALINEDIONE; 5,7 DICHLOROKYNURENIC ACID; 6,7 DIBROMO 5 NITRO 2,3 QUINOXALINEDIONE; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; 6,7 DIMETHYL 5 NITRO 2,3 QUINOXALINEDIONE; 7 CHLORO 4 HYDROXY 3 (3 PHENOXYPHENYL) 2 QUINOLONE; [1,2,3,4 TETRAHYDRO 7 (1H IMIDAZOL 1 YL) 6 NITRO 2,3 DIOXO 1 QUINOXALINYL]ACETIC ACID; [2 (8,9 DIOXO 2,6 DIAZABICYCLO[5.2.0]NON 1(7) EN 2 YL)ETHYL]PHOSPHONIC ACID; ACEA 1416; AMANTADINE; AV 101; AZD 2066; AZD 4282; AZD 9272; CHF 3381; CNS 5161; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; DECAHYDRO 6 PHOSPHONOMETHYL 3 ISOQUINOLINECARBOXYLIC ACID; DEXTROMETHORPHAN; DIZOCILPINE; EVT 101; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; GYK 152466; KETAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; QUINIDINE; RGH 896; TRAXOPRODIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ALLODYNIA; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTINOCICEPTION; ANXIETY; CHRONIC PAIN; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIABETIC NEUROPATHY; DIZZINESS; DRUG STRUCTURE; DRUG TARGETING; EPILEPSY; HALLUCINATION; HEAD INJURY; HUMAN; HUNTINGTON CHOREA; HYPERALGESIA; INFLAMMATION; INVOLUNTARY MOVEMENT; NEUROPATHIC PAIN; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; PHANTOM PAIN; POSTHERPETIC NEURALGIA; REVIEW; SEDATION; SIDE EFFECT; STROKE; TRAUMATIC BRAIN INJURY; UNSPECIFIED SIDE EFFECT;

ANIMALS; DRUG DELIVERY SYSTEMS; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; NEURALGIA; PAIN; TREATMENT OUTCOME;

EID: 69149092681     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220903029210     Document Type: Review

References (98)

1. Gilron I, Coderre TJ. Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs 2007;12:113-126
2. Ueda H, Rashid MH. Molecular mechanisms of neuropathic pain. Drug News Perspect 2003;16:605-613 •• An excellent review that highlights the pathophysiology of neuropathic pain.
3. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 2004;10:685-692 (Pubitemid 38937632)
4. Yogeeswari P, Ragavendran JV, Sriram D. Neuropathic pain: strategies in drug discovery and treatment. Expert Opin Drug Discov 2007;2:169-184 •• The review gives an overview of newer trends in neuropathic pain drug discovery. (Pubitemid 47078694)
5. Kew JN, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology 2005;179:4-29 (Pubitemid 40576690)
6. Schaible HG. Peripheral and central mechanisms of pain generation. Handb Exp Pharmacol 2007;177:3-28
7. Fundytus ME. Glutamate receptors and nociception: implications for the drug treatment of pain. CNS Drugs 2001;15:29-58 • An extensive review discussing the role of glutaminate receptors in pain pathophysiology.
8. Bleakman D, Alt A, Nisenbaum ES. Glutamate receptors and pain. Semin Cell Dev Biol 2006;17:592-604
9. Dickenson AH. A cure for wind up: NMDA receptor antagonists as potential analgesics. Trends Pharmacol Sci 1990;11:307-309 • The review discusses the role of glutamate in wind up phenomenon.
10. Mayer ML. Glutamate receptor ion channels. Curr Opin Neurobiol 2005;15:282-288
11. Schoepp DD, Jane DE, Monn JA. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999;38:1431-1476 (Pubitemid 29457728)
12. Paoletti P, Neyton J. NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol 2007;7:39-47 (Pubitemid 46238036)
13. Lu CR, Willcockson HH, Phend KD, et al. Ionotropic glutamate receptors are expressed in GABAergic terminals in the rat super?cial dorsal horn. J Comp Neurol 2005;486:169-178
14. Bennett AD, Everhart AW, Hulsebosch CE. Intrathecal administration of an NMDA or a non-NMDA receptor antagonist reduces mechanical but not thermal allodynia in a rodent model of chronic central pain after spinal cord injury. Brain Res 2000;859:72-82
15. Harris JA, Corsi M, Quartaroli M, et al. Upregulation of spinal glutamate receptors in chronic pain. Neuroscience 1996;74:7-12 (Pubitemid 26291143)
16. Xu H, Wu LJ, Zhao MG, et al. Presynaptic regulation of the inhibitory transmission by GluR5-containing kainate receptors in spinal substantia gelatinosa. Mol Pain 2006;2:29 (Pubitemid 44468852)
17. Varney MA, Gereau RW. Metabotropic glutamate receptor involvement in models of acute and persistent pain: prospects for the development of novel analgesics. Curr Drug Targets 2002;1:215-225
18. Neugebauer V, Carlton SM. Peripheral metabotropic glutamate receptors as drug targets for pain relief. Expert Opin Ther Targets 2002;6:349-361 (Pubitemid 34685444)
19. Maione S, Marabese I, Leyva J, et al. Characterisation of mGluRs which modulate nociception in the PAG of the mouse. Neuropharmacology 1998;37:1475-1483 (Pubitemid 28550421)
20. Salt TE, Binns KE. Contributions of mGlu1 and mGlu5 receptors to interactions with N-methyl-D-aspartate receptor-mediated responses and nociceptive sensory responses of rat thalamic neurons. Neuroscience 2000;100:375-380
21. Lourenco NF, Schadrack J, Berthele A, et al. Differential distribution of metabotropic glutamate receptor subtype mRNAs in the thalamus of the rat. Brain Res 2000;854:93-105 (Pubitemid 30067665)
22. Suter MR. Wen Y-R, Decosterd IS. Do glial cells control pain? Do glial cells control pain? Neuron Glia Biol 2007;3:255-268
23. Sung B, Lim G, Mao J. Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats. J Neurosci 2003;23:2899-2910 • The paper discusses the role of spinal glutamate transporters in neuropathic pain. (Pubitemid 36418626)
24. Sung B, Wang S, Zhou B, et al. Altered spinal arachidonic acid turnover after peripheral nerve injury regulates regional glutamate concentration and neuropathic pain behaviors in rats. Pain 2007;131:121-131 (Pubitemid 47193212)
25. Binns BC, Huang Y, Goettl VM, et al. Glutamate uptake is attenuated in spinal deep dorsal and ventral horn in the rat spinal nerve ligation model. Brain Res 2005;1041:38-47 (Pubitemid 40445387)
26. Lea PM, Wroblewska B, Sarvey JM, et al. β-NAAG rescues LTP from blockade by NAAG in rat dentate gyrus via the type 3 metabotropic glutamate receptor. J Neurophysiol 2001;85:1097-1106 (Pubitemid 32209597)
27. Fuhrman S, Palkovits M, Cassidy M, et al. The regional distribution of N-acetylaspartylglutamate (NAAG) and peptidase activity against NAAG in the rat nervous system. J Neurochem 1994;62:275-281 (Pubitemid 24010649)
28. Thomas AG, Wozniak KM, Tsukamoto T, et al. Glutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategy. Adv Exp Med Biol 2006;576:327-337
29. Zhou J, Neale JH, Pomper MG, et al. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov 2005;4:1015-1026 •• An excellent review about the potential of NAAG peptidase inhibitors in the treatment of various diseases.
30. Mercadante S, Arcuri E, Tirelli W, et al. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000;20:246-252 (Pubitemid 30750763)
31. Sen S, Aydin ON, Aydin K. Beneficial effect of low-dose ketamine addition to epidural administration of morphine-bupivacaine mixture for cancer pain in two cases. Pain Med 2006;7:166-169
32. Akin Takmaz S, Inan N, Günal S, et al. Ketamine combined with morphine for the management of cancer pain in a patient with meperidine tolerance and addiction. Agri 2005;17:44-47 (Pubitemid 41360793)
33. Hao JX, Xu XJ. Treatment of a chronic allodynia-like response in spinally injured rats: effects of systemically administered excitatory amino acid receptor antagonists. Pain 1996;66:279-285 (Pubitemid 26283998)
34. Thisted RA, Klaff L, Schwartz SL, et al. Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study. Clin Ther 2006;28:1607-1618 (Pubitemid 44848367)
35. Ben AR, Marouani N, Weinbroum AA. Dextromethorphan mitigates phantom pain in cancer amputees. Ann Surg Oncol 2003;10:268-274 (Pubitemid 40486960)
36. Carlsson KC, Hoem NO, Moberg ER, et al. Analgesic effect of dextromethorphan in neuropathic pain. Acta Anaesthesiol Scand 2004;48:328-336 (Pubitemid 38295345)
37. Gilron I, Booher SL, Rowan MS, et al. A randomized, controlled trial of high-dose dextromethorphan in facial neuralgias. Neurology 2000;55(7):964-971 (Pubitemid 30764358)
38. Carlsson KC, Hoem NO, Moberg ER, et al. Analgesic effect of dextromethorphan in neuropathic pain. Acta Anaesthesiol Scand 2004;48:328-336 (Pubitemid 38295345)
39. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist- a review of preclinical data. Neuropharmacology 1999;38:735-767 (Pubitemid 29187336)
40. Wiech K, Kiefer RT, Töpfner S, et al. A placebo-controlled randomized crossover trial of the N-methyl-D-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain. Anesth Analg 2004;98:408-413 (Pubitemid 38129389)
41. Maier C, Dertwinkel R, Mansourian N, et al. Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain-results of a randomized double-blinded, placebo-controlled trial. Pain 2003;103:277-283 (Pubitemid 36638817)
42. Schifitto G, Yiannoutsos CT, Simpson DM, et al. Adult AIDS Clinical Trials Group (ACTG) 301 TEAM. A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy. J Neurovirol 2006;12:328-331
43. Fukui S, Komoda Y, Nosaka S. Clinical application of amantadine, an NMDA antagonist for neuropathic pain. J Anesth 2001;15:179-181 (Pubitemid 32899064)
44. Davis AM, Inturrisi CE. Attenuation of hyperalgesia by LY235959, a competitive N-methyl-D-aspartate receptor antagonist. Brain Res 2001;894:150-153
45. Fairbanks CA, Schreiber KL, Brewer KL, et al. Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury. Proc Natl Acad Sci USA 2000;97:10584-10589
46. Villetti G, Bergamaschi M, Bassani F, et al. Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 2003;306:804-814 (Pubitemid 36886183)
47. Childers WE Jr, Abou-Gharbia MA, Moyer JA, et al. EAA-090: neuroprotectant competitive NMDA antagonist. Drugs Future 2002;27:633-638
48. Chizh BA, Headley PM. NMDA antagonists and neuropathic pain-multiple drug targets and multiple uses. Curr Pharm Des 2005;11:2977-2994 •• This is an excellent review that discusses various NMDA receptor sites as targets for neuropathic pain.
49. Boyce S, Wyatt A, Webb JK, et al. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology 1999;38:611-623 (Pubitemid 29150316)
50. Gogas KR. Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr Opin Pharmacol 2006;6:68-74 • The review describes the advantages of NR2B antagonists over classical NMDA antagonists.
51. Nakazato E, Kato A, Watanabe S. Brain but not spinal NR2B receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist CP-101,606 in a rat chronic constriction injury model. Pharmacology 2005;73:8-14 (Pubitemid 39664216)
52. Taniguchi K, Shinjo K, Mizutani M, et al. Antinociceptive activity of CP-101 606, an NMDA receptor NR2B subunit antagonist. Br J. Pharmacol 1997;122:809-812
53. Wang GM, Tian YK, Chen JP, et al. Evaluation of NR2B peptide as subunit vaccines against experimental neuropathic pain. Chin Med J 2007;120:643-647
54. Wallace MS, Rowbotham MC, Katz NP. A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain. Neurology 2002;59:1694-1700 (Pubitemid 35424448)
55. Quartaroli M, Fasdelli N, Bettelini L, et al. GV196771A, an NMDA receptor/glycine site antagonist, attenuates mechanical allodynia in neuropathic rats and reduces tolerance induced by morphine in mice. Eur J Pharmacol 2001;430:219-227 (Pubitemid 33050041)
56. Bordi F, Quartaroli M. Modulation of nociceptive transmission by NMDA/ glycine site receptor in the ventroposterolateral nucleus of the thalamus. Pain 2000;84:213-224 (Pubitemid 30074223)
57. Woodward RM, Huettner JE, Guastella J, et al. In vitro pharmacology of ACEA-1021 and ACEA-1031: systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites. Mol Pharmacol 1995;47:568-581
58. Woodward RM, Huettner JE, Tran M, et al. Pharmacology of 5-chloro-7- trifluoromethyl-1,4-dihydro-2,3- quinoxalinedione: a novel systemically active ionotropic glutamate receptor antagonist. J Pharmacol Exp Ther 1995;275:1209-1218 (Pubitemid 26130631)
59. Lutfy K, Doan P, Nugyen M, et al. ACEA-1328, an NMDA receptor antagonist, increases the potency of morphine and U50,488H in the tail flick test in mice. Pharmacol Res 1998;38:453-460 (Pubitemid 29002266)
60. Martinez V, Christensen D, Kayser V. The glycine/NMDA receptor antagonist (+)-HA966 enhances the peripheral effect of morphine in neuropathic rats. Pain 2002;99:537-545 (Pubitemid 35291072)
61. Zhu YP, Long ZH, Zheng ML, et al. Effect of glycine site/NMDA receptor antagonist MRZ2/576 on the conditioned place preference and locomotor activity induced by morphine in mice. J Zhejiang Univ Sci B 2006;7:998-1005
62. Christoph T, Reissmüller E, Schiene K, et al. Antiallodynic effects of NMDA glycine(B) antagonists in neuropathic pain: possible peripheral mechanisms. Brain Res 2005;1048:218-227 (Pubitemid 40803505)
63. Szekely JI, Torok K, Mate G. The role of ionotropic glutamate receptors in nociception with special regard to the AMPA binding sites. Curr Pharm Des 2002;8:887-912 (Pubitemid 34506368)
64. Nishiyama T, Gyermek L, Lee C, et al. The spinal antinociceptive effects of a novel competitive AMPA receptor antagonist, YM872, on thermal or formalin-induced pain in rats. Anesth Analg 1999;89:143-147 (Pubitemid 29293322)
65. Schoffnegger D, Ruscheweyh R, Sandkühler J. Spread of excitation across modality borders in spinal dorsal horn of neuropathic rats. Pain 2008;135:300-310
66. Chen SR, Eisenach JC, Mccaslin PP, et al. Synergistic effect between intrathecal non-NMDA antagonist and gabapentin on allodynia induced by spinal nerve ligation in rats. Anesthesiology 2000;92:500-506
67. Blackburn-Munro G, Bomholt SF, Erichsen HK. Behavioural effects of the novel AMPA/GluR5 selective receptor antagonist NS1209 after systemic administration in animal models of experimental pain. Neuropharmacology 2004;47:351-362 (Pubitemid 38953226)
68. Ta LE, Dionne RA, Fricton JR, et al. SYM-2081 a kainate receptor antagonist reduces allodynia and hyperalgesia in a freeze injury model of neuropathic pain. Brain Res 2000;858:106-120
69. Turner MS, Hamamoto DT, Hodges JS, et al. SYM 2081, an agonist that desensitizes kainate receptors, attenuates capsaicin and inflammatory hyperalgesia. Brain Res 2003;973:252-264
70. Lee HJ, Pogatzki-Zahn EM, Brennan TJ. The effect of the AMPA/kainate receptor antagonist LY293558 in a rat model of postoperative pain. J Pain 2006;768-777 (Pubitemid 44466694)
71. Gilron I, Max MB, Lee G, et al. Effects of the 2-amino-3-hydroxy-5- methyl-4-isoxazole-proprionic acid/kainate antagonist LY293558 on spontaneous and evoked postoperative pain. Clin Pharmacol Ther 2000;68:320-327
72. Gilron I. LY-293558. Eli Lilly and Co. Curr Opin Investig Drugs 2001;2:1273-1278
73. Schkeryantz JM, Kingston AE, Johnson MP. Prospects for metabotropic glutamate 1 receptor antagonists in the treatment of neuropathic pain. J Med Chem 2007;50:2563-2568 (Pubitemid 46896060)
74. Kohara A, Nagakura Y, Kiso T, et al. Antinociceptive profile of a selective metabotropic glutamate receptor 1 antagonist YM-230888 in chronic pain rodent models. Eur J Pharmacol 2007;571:8-16 (Pubitemid 47284045)
75. Han JS, Neugebauer V. mGluR1 and mGluR5 antagonists in the amygdale inhibit different components of audible and ultrasonic vocalizations in a model of arthritic pain. Pain 2005;113:211-222
76. Zhu CZ, Wilson SG, Mikusa JP, et al. Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities. Eur J Pharmacol 2004;506:107-118 (Pubitemid 39592907)
77. Osikowicz M, Mika J, Makuch W, et al. Glutamate receptor ligands attenuate allodynia and hyperalgesia and potentiate morphine effects in a mouse model of neuropathic pain. Pain 2008;139:117-126
78. Varty GB, Grilli M, Forlani A, et al. The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles. Psychopharmacology 2005;179:207-217 (Pubitemid 40576708)
79. Dogrul A, Ossipov MH, Lai J, et al. Peripheral and spinal antihyperalgesic activity of SIB-1757, a metabotropic glutamate receptor (mGluR5) antagonist, in experimental neuropathic pain in rats. Neurosci Lett 2000;292:115-118 •• A good review summarizing potential of mGLR1 antagonists for neuropathic pain drug discovery. (Pubitemid 30682329)
80. Du J, Zhou S, Carlton SM. Group II metabotropic glutamate receptor activation attenuates peripheral sensitization in inflammatory states. Neuroscience 2008;154:754-766
81. Jang JH, Kim DW, Sang NT, et al. Peripheral glutamate receptors contribute to mechanical hyperalgesia in a neuropathic pain model of the rat. Neuroscience 2004;128:169-176 (Pubitemid 39140690)
82. Goudet C, Chapuy E, Alloui A, et al. Group III metabotropic glutamate receptors inhibit hyperalgesia in animal models of inflammation and neuropathic pain. Pain 2007;137:112-124 (Pubitemid 351802243)
83. Coderre TJ, Kumar N, Lefebvre CD, et al. A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. J Neurochem 2007;100:1289-1299 (Pubitemid 46246405)
84. Yamamoto T, Nozaki-Taguchi N, Sakashita Y, et al. Inhibition of spinal N-acetylated-α-linked acidic dipeptidase produces an antinociceptive effect in the rat formalin test. Neuroscience 2001;102:473-479 (Pubitemid 32126501)
85. Yamamoto T, Nozaki-Taguchi N, Sakashita Y. Spinal N-acetyl-α-linked acidic dipeptidase (NAALADase) inhibition attenuates mechanical allodynia induced by paw carrageenan injection in the rat. Brain Res 2001;909:138-144 (Pubitemid 32710127)
86. Nagel J, Belozertseva I, Greco S, et al. Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain relation to brain concentration. Neuropharmacology 2006;51:1163-1171 (Pubitemid 44715967)
87. Long JB, Yourick DL, Slusher BS, et al. Inhibition of glutamate carboxypeptidase II (NAALADase) protects against dynorphin A-induced ischemic spinal cord injury in rats. Eur J Pharmacol 2005;508:115-122
88. Van Der Post JP, De Visser SJ, De Kam ML, et al. The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693. Br J Clin Pharmacol 2005;60:128-136
89. Zhang W, Murakawa Y, Wozniak KM, et al. The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy. J Neurol Sci 2006;247:217-223 (Pubitemid 44301265)
90. Yamamoto T, Hirasawa S, Wroblewska B, et al. Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model. Eur J Neurosci 2004;20:483-494 (Pubitemid 38969633)
91. Majer P, Jackson PF, Delahanty G, et al. Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem 2003;46:1989-1996 (Pubitemid 36532241)
92. Majer P, Hin B, Stoermer D, et al. Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1′ side chain. J Med Chem 2006;49:2876-2885 (Pubitemid 43749154)
93. Chiang CY, Wang J, Xie YF, et al. Astroglial glutamate-glutamine shuttle is involved in central sensitization of nociceptive neurons in rat medullary dorsal horn. J Neurosci 2007;27:9068-9076 (Pubitemid 47312060)
94. Parsons CG. NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol 2001;429:71-78
95. Low SJ, Roland CL. Review of NMDA antagonist-induced neurotoxicity and implications for clinical development. Int J Clin Pharmacol Ther 2004;42:1-14 •• The review describes the toxicity issues in development of NMDA antagonists.
96. Muir KW, Grosset DG, Gamzu E, et al. Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers. Br J Clin Pharmacol 1994;38:33-38 (Pubitemid 24222833)
97. Roegel Jean-Christophe and Eftekhari Pierre. Novel uses for drugs targeting glutamine synthetase. WO017768; 2007
98. Board of Regents of University of Okhalama. Method of alleviating chronic pain via peripheral glutaminase regulation. US7288246; 2007